ImmunoCellular Therapeutics, Ltd Enters into Option Agreement with The University of Texas MD Anderson Cancer Center for a Novel Cancer Stem Cell Therapy

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs. This latest agreement bolsters the Company’s portfolio of technologies targeting CSCs. This portfolio already features several promising therapies, including ICT-107, a dendritic cell based immunotherapy that recently completed a phase I study, and ICT-121, an off-the-shelf peptide targeting CSCs.